Dietary Intervention Replacing Carbohydrate With Protein and Fat Has Greater Effect on Peripheral Blood Mononuclear Cell Metabolites Than on Plasma Metabolites in Patients With Prediabetes or Type-2 Diabetes
- Conditions
- Type-2 DiabetesPrediabetes
- Interventions
- Dietary Supplement: Dietary intervention-refined riceDietary Supplement: Dietary intervention-whole grains and legumes
- Registration Number
- NCT02191644
- Lead Sponsor
- Yonsei University
- Brief Summary
This study examined whether dietary-induced reductions in lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in peripheral blood mononuclear cells (PBMC) and plasma affected metabolic profiles in PBMCs and plasma.
- Detailed Description
Eighty nonobese patients (aged 40-70 years) with prediabetes or newly diagnosed type-2 diabetes were randomly assigned to a control group (normal diet with refined rice) or a whole-grain group (replacement of refined rice with whole-grains and legumes). This dietary intervention replaced approximately 7% of carbohydrate-derived energy with approximately 4% of protein-derived energy and approximately 3% of fat-derived energy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 82
- subjects who had IFG (100≤ fasting glucose <126 mg/dL)
- or newly diagnosed type-2 diabetes (fasting glucose ≥126 mg/dL)
- current and/or past history of cardiovascular disease including angina
- liver or kidney dysfunction
- thyroid or pituitary disease
- pregnancy or lactation
- taking medications or supplements
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Refined rice Dietary intervention-refined rice - Whole grains and legumes Dietary intervention-whole grains and legumes -
- Primary Outcome Measures
Name Time Method Lp-PLA2 Activity in Plasma Change from baseline in Lp-PLA2 at 12 weeks Lp-PLA2 Activity in PBMC Change from baseline in Lp-PLA2 at 12 weeks
- Secondary Outcome Measures
Name Time Method PBMC metabolites Change in L-leucine, oleamide, lysoPC (16:0), and lysoPC (18:0)
Trial Locations
- Locations (1)
Yonsei University
🇰🇷Seoul, Korea, Republic of